CD44 and breast carcinoma: In the present study, we evaluated the effect of CB1 agonist and antagonist on proliferation and invasion potential of (CD44+/CD24-/low/ESA+) human breast cancer stem cells which were derived from MDA-MB-231 and their parental cells.